Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.